^
Association details:
| Biomarker: | DNMT3A mutation |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) + benmelstobart (APL-502) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer
Published date:
11/17/2023
Excerpt:
Patients with wildtype DNMT3A had a lower response rate than patients with mutated DNMT3A (5/22, 23% vs. 2/4, 50%)…To the best of our knowledge, this is the first investigation that establishes bTMB and MSAF as biomarkers associated with treatment response and survival outcomes of pretreated aTNBC patients receiving combined immunotherapy and antiangiogenic therapy.
DOI:
10.1038/s41392-023-01672-5
Trial ID:
